VKTX vs. CERE, ITCI, CYTK, JAZZ, ASND, ELAN, APLS, IONS, LEGN, and BPMC
Should you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Cerevel Therapeutics (CERE), Intra-Cellular Therapies (ITCI), Cytokinetics (CYTK), Jazz Pharmaceuticals (JAZZ), Ascendis Pharma A/S (ASND), Elanco Animal Health (ELAN), Apellis Pharmaceuticals (APLS), Ionis Pharmaceuticals (IONS), Legend Biotech (LEGN), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Viking Therapeutics (NASDAQ:VKTX) and Cerevel Therapeutics (NASDAQ:CERE) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment, valuation and community ranking.
76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 87.7% of Cerevel Therapeutics shares are owned by institutional investors. 4.7% of Viking Therapeutics shares are owned by insiders. Comparatively, 5.1% of Cerevel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Viking Therapeutics had 6 more articles in the media than Cerevel Therapeutics. MarketBeat recorded 13 mentions for Viking Therapeutics and 7 mentions for Cerevel Therapeutics. Viking Therapeutics' average media sentiment score of 0.65 beat Cerevel Therapeutics' score of 0.62 indicating that Viking Therapeutics is being referred to more favorably in the media.
Viking Therapeutics' return on equity of -27.78% beat Cerevel Therapeutics' return on equity.
Viking Therapeutics is trading at a lower price-to-earnings ratio than Cerevel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Viking Therapeutics has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Cerevel Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.
Viking Therapeutics received 441 more outperform votes than Cerevel Therapeutics when rated by MarketBeat users. Likewise, 80.00% of users gave Viking Therapeutics an outperform vote while only 66.52% of users gave Cerevel Therapeutics an outperform vote.
Viking Therapeutics presently has a consensus target price of $112.25, suggesting a potential upside of 72.88%. Cerevel Therapeutics has a consensus target price of $41.40, suggesting a potential downside of 1.41%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Cerevel Therapeutics.
Summary
Viking Therapeutics beats Cerevel Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Viking Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viking Therapeutics Competitors List
Related Companies and Tools
